Drug | Pharmacologic Class | Indication | More Information |
Endocrine Disorders | |||
Tlando™ (testosterone undecanoate) | Androgen | For testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. | FDA Approves Oral Testosterone Replacement Therapy Tlando |
Gastrohepatic Disorders | |||
Rinvoq® (upadacitinib) | Janus kinase inhibitor | Adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to 1 or more TNF blockers. | Rinvoq Drug Monograph |
Neurologic Disorders | |||
Adlarity® (donepezil transdermal system | Acetylcholinesterase inhibitor | Treatment of mild, moderate, and severe dementia of the Alzheimer type. | Donepezil Transdermal Patch Approved for Alzheimer Disease |
Fintepla® (fenfluramine) Oral Solution | Sympathomimetic | Treatment of seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older. | Fintepla Drug Monograph |
Oncology | |||
Lynparza® (olaparib) | Poly (ADP-ribose) polymerase (PARP) inhibitor | Adjuvant treatment of patients with deleterious or suspected deleterious germline BRCA-mutated human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. | Lynparza Drug Monograph |
Opdivo® (nivolumab) | Programmed death receptor-1 (PD-1) blocking antibody | In combination with platinum-doublet chemotherapy, for neoadjuvant treatment of adult patients with resectable (tumors ≥4cm or node positive) non-small cell lung cancer. | Opdivo Drug Monograph |
Opdualag™ (nivolumab and relatlimab-rmbw) | PD-1 blocking antibody and lymphocyte activation gene-3 blocking antibody | For the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. | Opdualag Drug Monograph |
Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) | Radioligand therapeutic agent | For the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. | Pluvicto Approved for PSMA-Positive Metastatic Castration-Resistant Prostate Cancer |
Publish Date